Y-mAbs Therapeutics’ (YMAB) “Outperform” Rating Reaffirmed at Wedbush

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “outperform” rating reaffirmed by stock analysts at Wedbush in a research note issued on Monday,RTT News reports. They presently have a $23.00 price target on the stock. Wedbush’s price target indicates a potential upside of 343.16% from the company’s current price.

A number of other analysts also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. Oppenheimer began coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 price target for the company. Finally, Brookline Capital Management assumed coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective for the company. One research analyst has rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $20.89.

Y-mAbs Therapeutics Trading Down 6.7 %

Shares of YMAB traded down $0.37 during mid-day trading on Monday, reaching $5.19. 429,703 shares of the stock traded hands, compared to its average volume of 469,408. Y-mAbs Therapeutics has a 1 year low of $5.13 and a 1 year high of $19.12. The company has a market cap of $232.45 million, a price-to-earnings ratio of -9.61 and a beta of 0.67. The firm has a fifty day moving average price of $6.58 and a 200 day moving average price of $10.72.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Acorn Capital Advisors LLC purchased a new stake in shares of Y-mAbs Therapeutics during the fourth quarter valued at approximately $22,408,000. Caligan Partners LP increased its position in shares of Y-mAbs Therapeutics by 105.3% in the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock valued at $15,718,000 after acquiring an additional 613,175 shares during the period. State Street Corp raised its stake in shares of Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after acquiring an additional 405,169 shares during the last quarter. Infinitum Asset Management LLC purchased a new stake in shares of Y-mAbs Therapeutics during the fourth quarter worth about $1,218,000. Finally, Paradigm Biocapital Advisors LP grew its stake in shares of Y-mAbs Therapeutics by 3.7% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company’s stock worth $33,171,000 after purchasing an additional 150,000 shares during the last quarter. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.